Recruiting

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Sponsor:

James A. Tumlin, MD

Code:

NCT03502031

Conditions

Renal Insufficiency, Chronic

Diabetic Nephropathy Type 2

Eligibility Criteria

Sex: All

Age: 75+

Healthy Volunteers: Not accepted

Interventions

Renin-Angiotensin (RAAS) alone

Renin-Angiotensin (RAAS) blockers in combination with Spironolactone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information